newsfilter
← Latest News
Business Wire·

CEL-SCI Announces Pricing of $2.5 Million Offering

CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of a best-efforts offering of 16,000,000 shares of its common stock (or pre-funded